Cargando…
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy
Cancer immunotherapy using monoclonal antibodies targeting immune checkpoints has undoubtedly revolutionized the cancer treatment landscape in the last decade. Immune checkpoint inhibitors can elicit long-lasting, previously unheard-of responses in a number of tumor entities. Yet, even in such tumor...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986721/ https://www.ncbi.nlm.nih.gov/pubmed/35353346 http://dx.doi.org/10.1007/s40259-022-00521-1 |